secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0001493152-24-035737
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell reports median OS of 15.6 months in Phase 2 Bria-IMT study; FDA path cleared for Bria-PROS+
--------------------------------------------------------------------------------

- Median overall survival of 15.6 months in 25 patients receiving Phase 3 Bria-IMT formulation vs 6.7–9.3 months in literature controls.
- FDA Pre-IND meeting gave positive feedback; waived animal toxicology/PK studies for Bria-PROS+ prostate cancer trial.
- No drug-related discontinuations reported in the Phase 2 study; ongoing Phase 3 pivotal study NCT06072612.
- Poster presentation at SITC 2024 (Nov 8, Houston) on novel targeted immunotherapy candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224035737/0001493152-24-035737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224035737/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-035737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer